Skip to content

Restarting Early versus Later Anticoagulation for Chronic Subdural Hematoma with Atrial Fibrillation (RELACS)

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521179-29-00
Acronym
RELACS
Enrollment
332
Registered
2025-06-04
Start date
2025-07-06
Completion date
Unknown
Last updated
2025-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation, Chronic subdural hematoma

Brief summary

Thromboembolic events (ischemic stroke, systemic embolism), Hemorrhagic events, Vascular death

Detailed description

All-cause mortality, modified Rankin Scale, Reoperation of ipsilateral hematoma, Number and type of unscheduled emergency radiological examinations, Number of emergency department visits, Postoperative total hospitalization days, counted from the day of surgery, Separation of the components of the primary outcome

Interventions

DRUGEDOXABAN
DRUGAPIXABAN
DRUGWARFARIN
DRUGDABIGATRAN ETEXILATE
DRUGRIVAROXABAN

Sponsors

HUS-Yhtymae
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Thromboembolic events (ischemic stroke, systemic embolism), Hemorrhagic events, Vascular death

Secondary

MeasureTime frame
All-cause mortality, modified Rankin Scale, Reoperation of ipsilateral hematoma, Number and type of unscheduled emergency radiological examinations, Number of emergency department visits, Postoperative total hospitalization days, counted from the day of surgery, Separation of the components of the primary outcome

Countries

Finland, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026